Final Analysis of Results from the Phase Ib/II Trial of Romidepsin and CHOP in Previously Untreated PTCL


Final Analysis of Results from the Phase Ib/II Trial of Romidepsin and CHOP in Previously Untreated PTCL
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/6/15)
Dupuis J et al. Final analysis of the RO-CHOP phase Ib/II study: Romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL). Proc ASH 2014;Abstract 504.

Dr Moskowitz is Clinical Director of the Division of Hematologic Oncology, Attending Physician in Lymphoma and Adult BMT Services, Member of Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.